NCT02966340View on ClinicalTrials.gov

Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

March 12, 2018

Study Completion Date

March 12, 2018

Conditions
Alcoholism
Interventions
DRUG

Prazosin

2mg Prazosin

DRUG

Placebo

Placebo

Trial Locations (1)

53706

University of Wisconsin, Madison

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT02966340 - Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment | Biotech Hunter | Biotech Hunter